Global Hypertension drugs Market

Pages : 185 | Category: | Publishers: Goldstein Research


Global Hypertension Drugs Market

Market Overview

Many therapeutic agents are utilized for the pharmacologic management of hypertension and the available antihypertensive agents are generally equally effective in lowering blood pressure however; there may be interpatient variability that can affect the way a patient will respond to one treatment over another. 5 mmHg blood pressure declination can reduce the risk of stroke by 34%, ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.

Goldstein Research analyst forecast the Hypertension Drugs Market size is set to reach USD 33.1 billion by 2024, at a CAGR of 1.12% over the forecast years.

Covered In This Global Hypertension Drugs Market Report

The report covers the present ground scenario and the future growth prospects of the Hypertension Drugs Market for 2016-2024 along with the total number of blood pressure cases worldwide. We calculated the market size and revenue share on the basis of revenue generated from major players and sales of Hypertension Drugs from major players across the globe.

Global Hypertension Drugs Market Segmentation

By Analysis Basis

Systemic Hypertension Drugs
Pulmonary Hypertension Drugs
By Therapy Type

Calcium Channel Blockers
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitor
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Based on Geography

North America (U.S. & Canada) Hypertension Drugs Market
Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Hypertension Drugs Market
Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Hypertension Drugs Market
Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Hypertension Drugs Market
Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Hypertension Drugs Market
On the basis of analysis, systemic hypertension drug accounted for 85% of global hypertension drugs market owing to enhanced patient awareness results in an early diagnosis of the disease followed by treatment.

Hypertension Drugs Market Outlook 2016-2024, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global Hypertension Drugs market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

Our global Hypertension Drugs Market report comprises of the following companies as the key players in the Hypertension Drugs Market: Lupin Limited, Novartis AG, Sun Pharmaceuticals LLC, Daiichi – Sankyo, Pfizer Inc., Sanofi S.A, AstraZeneca Plc., Johnson & Johnson Ltd., Boehringer Ingelheim, and Merck & Co, Roche, Abbott, GlaxoSmithKline plc., AstraZeneca, Bayer AG, Gilead, Actelion.

Other high-flying vendors in the market are: Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, Yuhan, Ono Pharmaceutical, Northern Therapeutics, Mast Therapeutics, Eiger BioPharmaceuticals.

According to our global market study on the basis of extensive primary and secondary research: “One trend is changing lifestyle which is responsible to cause disturbance in systolic and diastolic BP and can increase cardiovascular risk that can be measured by non-pharmacological as well as pharmacological means.”

According to the report, major driving factor for expansion of hypertension drugs market is the rising geriatric population. According to WHO, globally, 22% of adults aged over 18yrs had increased blood pressure and USA’s CDC (Centre for Disease control &prevention) articulated that 70 million American adults are suffering from high blood pressure with only approximately 52% i.e. half the patient pool had got the condition under control.

Further, the report states that the major challenge is patent expiry and increase in more market players hinders the market of big pharma giants like patent expiries of drugs such as Micardis, Avapro, and Diovan.

Based on geography, North America dominates the hypertension drugs market with almost 42% market share in 2016 due to the launch of new disease-modifying therapies. The immensely large patient pool in Asia, Europe and Africa is in itself a huge hypertension drugs market driver and hold the opportunities for future relevance.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For a full detailed overview, send us the sample request.

Key questions answered in this Hypertension Drugs Market report

What is the total market size by 2024 and what would be the expected growth rate of the market?
What is the revenue of Hypertension Drugs in 2015-16 and what would be the expected demand over the forecast period?
What are the key market trends?
What are the factors which are driving this market?
What are the major barriers to market growth?
Who are the key vendors in this market space?
What are the market opportunities for the existing and entry level players?
What are the recent developments and business strategy of the key players?

We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements